Clinical Trials Browser

Phase 1/2 × NIH × omipalisib × Clear all

NCT01989585 2026-03-19

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Phase 1/2 Active not recruiting

Melanoma

NCT02079740 2025-09-30

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

96 enrolled 30 charts

Neoplasm Metastasis